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Abstract  Chronic  obstructive  pulmonary  disease  (COPD)  is  one  of  the  most  common  chronic
diseases and  a  major  cause  of  morbidity  and  mortality.  An  imbalance  between  oxidants  and
antioxidants  (oxidative  stress)  has  been  proposed  as  a  critical  event  in  the  pathogenesis  of  COPD.
The increased  oxidative  stress  in  patients  with  COPD  is  the  result  of  exogenous  oxidants  namely
pollutants and  cigarette  smoke  as  well  as  endogenous  oxidant  production  during  inﬂammation.
The aim  of  the  present  study  was  to  clarify  the  hypothesis  about  the  presence  of  an  imbalance
between oxidants  and  the  antioxidant  defences  associated  to  COPD.  In  this  study,  we  evaluated
a biomarker  of  oxidative  stress  (malondialdehyde,  a  lipid  peroxidation  derived  product)  and
non-enzymatic  antioxidants  (vitamin  C  and  the  sulphydryl  groups)  in  COPD  patients  and  healthy
controls. The  marker  of  oxidative  stress  was  found  to  be  signiﬁcantly  (p  <  0.001)  higher  in  COPD
patients when  compared  with  control  group.  No  age  dependent  changes  in  the  plasma  levels  of
lipid peroxidation  products  were  found.  COPD  patients  had  a  signiﬁcant  (p  <  0.001)  decrease  in
antioxidant  status  as  compared  with  the  control  group.  Our  results  show  that  oxidative  stress
is an  important  pathophysiologic  change  in  COPD.
© 2012  Sociedade  Portuguesa  de  Pneumologia.  Published  by  Elsevier  España,  S.L.  All  rights
reserved.
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PALAVRAS-CHAVE
Doenc¸a pulmonar
obstrutiva  crónica;
Stress  oxidativo;
Peroxidac¸ão  lipídica;
Antioxidantes
Avaliac¸ão  do  equilíbrio  entre  oxidantes  e  antioxidantes  na  patogénese  da  doenc¸a
pulmonar  obstrutiva  crónica
Resumo  A  doenc¸a  pulmonar  obstrutiva  crónica  (DPOC)  é  uma  das  doenc¸as  crónicas  mais
comuns e  representa  uma  importante  causa  de  morbilidade  e  mortalidade.  Um  desequilíbrio
entre oxidantes  e  antioxidantes  (stress  oxidativo)  tem  sido  proposto  como  um  acontecimento
importante  na  patogénese  da  DPOC.  O  aumento  do  stress  oxidativo  em  doentes  com  DPOC  é
o resultado  da  presenc¸a  de  oxidantes  exógenos,  nomeadamente,  poluentes  e  fumo  do  tabaco,
assim como  oxidantes  endógenos  produzidos  durante  a  inﬂamac¸ão.  O  objetivo  do  presente
estudo consistiu  em  clariﬁcar  a  hipótese  sobre  a  existência  de  um  desequilíbrio  entre  oxidantes
e as  defesas  antioxidantes  associado  à  DPOC.  Neste  estudo,  avaliou-se  um  biomarcador  do
stress oxidativo  (malonildialdeído,  um  produto  resultante  da  peroxidac¸ão  lipídica)  e  antioxi-
dantes não-enzimáticos  (vitamina  C  e  grupos  sulﬁdrilo),  em  doentes  com  DPOC  e  em  controlos
saudáveis.  Observou-se  um  aumento  signiﬁcativo  (p  <  0,001)  do  marcador  do  stress  oxidativo
nos doentes  com  DPOC  comparativamente  ao  grupo  controlo.  Não  foram  encontradas  alterac¸ões
dependentes  da  idade  nos  níveis  dos  produtos  da  peroxidac¸ão  lipídica.  Os  doentes  DPOC  apre-
sentaram uma  diminuic¸ão  signiﬁcativa  (p  <  0,001)  do  status  antioxidante,  comparativamente
ao grupo  controlo.  Os  nossos  resultados  evidenciam  que  o  stress  oxidativo  representa  uma
importante  alterac¸ão  ﬁsiopatológica  na  DPOC.
© 2012  Sociedade  Portuguesa  de  Pneumologia.  Publicado  por  Elsevier  España,  S.L.  Todos  os
direitos reservados.
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The  ex-smokers  had  stopped  smoking  at  least  1  year  before
their  participation  in  the  study.  Fifty  healthy  subjects  (mean
age  41.60  ±  12.31  years;  12  female,  38  male  and  body  mass
index,  BMI  27.322  ±  4.310  kg/m2)  with  no  history  of  lung
Table  1  Clinical  and  physiological  characteristics  of  COPD
group.
Clinical  and  physiological  parameters Values
Age,  years 71,30  ±  7,68
Male/female,  n  11/9
Body mass  index,  kg/m2 27,918  ±  1,724
Smoking  status:  ex-smokers/non-smokers,  n  15/5
Packs-years  in  ex-smokers  68,8  ±  10,754
GOLD  stage:  I/II/IV,  n  2/4/14
FVC,  %  predicted  77,100  ±  5,190Introduction
Chronic  obstructive  pulmonary  disease  (COPD)  is  one  of  the
most  common  chronic  diseases  and  represents  an  important
cause  of  morbidity  and  mortality.1--3 Experimental  studies
have  provided  evidence  about  an  imbalance  between  oxi-
dants/antioxidants,  in  favor  of  reactive  oxidizing  species
(oxidative  stress),  associated  with  COPD.2,4--8 The  involve-
ment  of  oxidative  stress  in  the  pathogenesis  of  COPD  appears
to  be  crucial  for  the  manifestation  of  the  inﬂammatory
response  of  the  lung.9--13 The  increase  of  oxidative  stress
in  patients  with  COPD  results  from  the  action  of  exogenous
oxidants  (e.g.  air  pollutants  and  tobacco  components)  as
well  as  endogenous  oxidants  produced  during  the  inﬂam-
matory  process.  However,  there  are  numerous  inconsistent
results  in  the  studies  associated  with  oxidant  and  antiox-
idant  imbalance  in  the  pathogenesis  of  COPD.14,15 One  of
the  main  targets  of  oxidative  stress  are  the  polyunsaturated
fatty  acids  present  in  cell  membranes,16,17 the  oxidizing
species  leading  to  a  multistep  process  in  which  a  whole  is
classiﬁed  as  lipid  peroxidation.  There  are  several  products
resulting  from  lipid  peroxidation,  among  those  to  consider
is  a  dialdehyde  (malonyldialdehyde  [MDA])  which  has  a  rec-
ognized  effect  on  the  level  of  the  human  genome  and  is
considered  a  clastogenic  and  genotoxic  agent.18 This  means
that  the  evaluation  of  MDA  in  biological  samples  can  be  con-
sidered  as  an  indicator  of  increased  lipid  peroxidation  and,
therefore,  an  indicator  of  oxidative  damage  in  vivo.16,19,20
There  is  evidence  that  oxidative  stress  reaches  the  circu-
lation  by  a  fall  in  the  plasma  antioxidant  capacity  (vitamin  C,
vitamin  E,  -carotene  and  sulphydryls)  associated  to  smok-
ing.  In  addition,  a  similar  fall  in  plasma  antioxidant  occurs
in  exacerbations  of  COPD.5,13 Epidemiological  studies  have
shown  that  high  dietary  intake  of  antioxidants  vitamins  C
and  E  related  to  a  lower  prevalence  of  chronic  bronchitis  in
smokers.21The  main  objective  of  this  study  was  to  clarify  the
ypothesis  of  the  existence  of  an  imbalance  between  oxi-
ant  species  production  and  antioxidant  defence  associated
ith  the  pathogenesis  of  COPD.
aterials and methods
tudy  population
wenty  patients  (mean  age  71.30  ±  7.68  years)  with  stable
OPD  (at  least  more  than  6  months  without  exacerbation
istory)  were  studied.  Fifteen  of  them  had  a  past  history  of
moking  and  ﬁve  were  non-smokers,  with  passive  smoking
xposure  or  occupational  exposure.  Clinical  and  physiolog-
cal  characteristics  of  COPD  group  are  shown  in  Table  1.FEV1, %  predicted 58,130  ±  5,332
FEV1/FVC,  %  59,453  ±  3,805
paO2, mmHg  66,700  ±  2,71
7 C.  Cristóvão  et  al.
d
c
d
C
e
p
d
a
M
D
A
i
l
t
o
a
e
s
M
o
a
c
p
Q
V
b
w
c
a
T
D
T
o
g
u
a
g
T
a
t

S
T
t
n
t
u
w
Marker of Oxidative Stress
0
2
4
6
8
10
12
Controls COPD
non-smokers
Whole
COPD
COPD
ex-smokers
M
D
A 
(nm
ol/
mL
)
p<0.00 1p<0.00 1p<0.00 1
Figure  1  Levels  of  malondialdehyde  (MDA)  in  plasma  from
control  subjects  and  COPD  patients.  Values  are  expressed  as
mean ±  SEM.  p  <  0.001  signiﬁcantly  different  between  controls
and whole  COPD  group.  p  <  0.01  signiﬁcantly  different  between
controls and  non-smoker  patients.  p  <  0.001  signiﬁcantly  differ-
ent between  controls  and  ex-smoker  patients.  There  was  no
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h2  
isease  were  used  as  control  group.  Twelve  of  them  were
urrent  smokers  and  thirty-eight  had  never  smoked.
Oxidative  stress  was  assessed  in  plasma  through  the
etermination  of  the  levels  of  a  biomarker  such  as  MDA  in
OPD  patients  and  in  control  group.  Antioxidant  status  was
valuated  by  the  quantiﬁcation  of  vitamin  C  and  total  sul-
hydryl  (  SH)  groups,  using  spectrophotometric  methods.
The  study  was  conducted  according  to  the  rules  of  the
eclaration  of  Helsinki.  Informed  consent  was  obtained  from
ll  subjects  participating  in  the  study.
ethods
etermination  of  plasmatic  malonyldialdehyde
 biomarker  of  systemic  oxidative  stress  has  been  assessed
n  plasma  through  the  quantiﬁcation  of  the  levels  of  a
ipid  peroxidation  derived  product,  MDA.  MDA  concen-
rations  were  measured  spectrophotometrically  in  terms
f  thiobarbituric  acid  reactive  substances  (TBARS)  using
 spectrophotometric  method  modiﬁed  from  Ohkawa
t  al.22 The  absorbances  were  read  at  532  nm  corre-
ponding  to  the  colored  complex  formed  between  the
DA  and  thiobarbituric  acid  (TBA).  The  concentration
f  TBARS  was  calculated  using  the  MDA  concentration
nd  using  a  calibration  curve  previously  prepared.  The
oncentration  of  MDA  was  expressed  in  nmol/mL  of
lasma.
uantiﬁcation  of  vitamin  C
itamin  C  levels  were  monitored  by  the  method  described
y  Omaye  et  al.23 In  brief,  the  dinitrophenylhydrazine  reacts
ith  oxidized  vitamin  C  (oxidized  ascorbic  acid)  to  give  a
olored  product.  The  absorbance  was  measured  at  520  nm
nd  is  directly  proportional  to  the  vitamin  C  concentration.
he  levels  of  vitamin  C  were  expressed  in  g/mL  of  plasma.
etermination  of  non-protein  sulphydryl  groups
he  non-protein  sulphydryl  groups  are  mainly  in  the  form
f  reduced  glutathione  (GSH).  We  evaluated  the  sulphydryl
roup  using  a  spectrophotometric  method  involving  the
se  of  Ellman’s  reagent.24 The  5,5′-dithiobis(2-nitrobenzoic
cid)  (DTNB)  undergoes  disulﬁde  exchange  with  sulphydryl
roups  and  5-thio-2-nitrobenzoate  anion  (TNB)  is  formed.
he  absorbance  of  the  reduced  chromogen  was  measured
t  412  nm  and  is  directly  proportional  to  the  GSH  concen-
ration.  The  levels  of  sulphydryl  groups  were  expressed  in
mol/mL  of  plasma.
tatistical  analyses
he  results  are  expressed  as  mean  ±  SEM  of  the  concen-
rations  of  plasma  parameters  evaluated.  The  appropriate
onparametric  test  was  chosen  for  data  not  normally  dis-
ributed.  Comparisons  between  two  groups  were  tested
sing  unpaired  t-test  or  Mann--Whitney  U-test.  A  difference
ith  p  <  0.05  was  considered  statistically  signiﬁcant.
i
t
C
aigniﬁcant  differences  between  non-smokers  and  ex-smokers
OPD  patients.
esults
xidative  stress  and  antioxidant  status
he  plasma  concentrations  of  MDA,  vitamin  C  and  sul-
hydryl  groups  of  COPD  patients  (whole  group,  non-smoker
nd  ex-smoker  patients)  and  control  subjects  are  shown
n  Table  2.  The  marker  of  oxidative  stress  (TBARS  evalu-
ted  as  the  amount  of  MDA  produced)  was  found  to  be
igniﬁcantly  (p  <  0.001)  higher  in  COPD  patients  when  com-
ared  with  control  group.  Fig.  1  shows  the  MDA  plasma
evels  in  controls  and  COPD  patients.  We  did  not  ﬁnd  sig-
iﬁcant  differences  in  MDA  levels  associated  to  age  but
e  did  observe  a  signiﬁcant  difference  between  controls
nd  COPD  patients  non-smokers  (p  <  0.01)  and  ex-smokers
p  <  0.001).  Our  results  have  shown  no  signiﬁcant  difference
n  TBARS  in  ex-smokers  COPD  patients  as  compared  with  non-
mokers  COPD  patients.  However,  we  observed  an  increase
n  the  marker  of  oxidative  stress  associated  to  the  ex-smoker
atients.
COPD  patients  had  a  signiﬁcant  (p  <  0.001)  decrease  in
ntioxidant  status  (vitamin  C  and  sulphydryl  groups)  when
ompared  with  the  control  group  (Fig.  2).  No  signiﬁcant  dif-
erence  was  found  between  non-smokers  and  ex-smokers  in
OPD  patients.  But  we  observed  a  decrease  in  vitamin  C
ssociated  to  the  ex-smoker  patients.
iscussion and conclusions
xidants  promote  lipid  peroxidation  in  cell  membrane.  The
etection  of  a  product  of  lipid  peroxidation  in  plasma,
amely  MDA,  is  a  useful  tool  to  show  the  occurrence  of
n  oxidative  stress  in  vivo. The  aim  of  the  present  study
as  to  compare  the  production  of  MDA  and  the  levels  of
ntioxidants  vitamin  C  and  the  thiol  groups  in  COPD  and
ealthy  controls.  Our  results  show  that  oxidative  stress  is  an
mportant  pathophysiologic  change  in  COPD.  The  increase  in
he  lipid  peroxidation  products  in  plasma  of  patients  with
OPD,  supports  the  hypothesis  of  oxidative  stress  associ-
ted  with  the  disease.  According  to  our  results,  an  increased
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Table  2  Plasma  MDA  levels  and  antioxidant  status  of  the  study  groups.
Controls  (n  =  50)  Whole  COPD  group
(n =  20)
COPD  non-smokers
(n  =  5)
COPD  ex-smokers
(n  =  15)
MDA  (nmol/mL)  3.830  ±  0.310  8.549  ±  1.228  7.268  ±  2.309  8.976  ±  1.472
VitaminC (g/mL)  6.230  ±  0.220  1.866  ±  0.353  2.119  ±  0.770  1.782  ±  0.408
Sulphydryl groups  (mol/mL)  0.275  ±  0.011  0.135  ±  0.022  0.130  ±  0.021  0.137  ±  0.029
p
a
g
a
t
d
a
r
s
C
e
l
s
h
t
c
s
t
l
m
t
a
n
n
a
C
p
oAll data are expressed as mean ± SEM.
oxidative  stress  is  most  evident  in  patients  with  smok-
ing  status, but  we  did  not  ﬁnd  signiﬁcant  differences  in
lipid  peroxidation  and  antioxidant  status  in  non-smokers
and  ex-smokers  patients.  In  addition,  we  did  not  observe
any  signiﬁcant  difference  in  the  marker  of  oxidative  stress
and  antioxidant  status  between  healthy  smokers  and  non-
smokers.  Rahman  et  al.25 observed  that  in  smokers  with
and  without  COPD,  an  end  product  of  lipid  peroxidation
is  formed  in  airway  epithelial  cells,  endothelial  cells,  neu-
trophils  and  macrophages.  They  concluded  that  oxidative
stress  resulting  from  cigarette  smoking  appears  to  be  more
pronounced  in  those  who  developed  COPD.  Previous  studies
by  other  authors  showed  no  correlation  between  TBARs  and
hydrogen  peroxide  levels  in  the  COPD  associated  to  cigarette
smoking.26 Although  our  results  should  be  regarded  as  pre-
liminary,  we  observed  a  tendency  for  an  increase  in  MDA
levels  associated  to  COPD  patients  with  smoking  habits.
Antioxidants  are  also  markers  of  oxidative  stress.  We  can
deﬁne  an  antioxidant  as  any  substance  that,  when  present
at  low  concentrations,  compared  with  those  of  the  oxidiz-
able  substrate,  considerably  delays  or  inhibits  oxidation  of
the  substrate.16 Antioxidants  can  act  at  several  different
stages  in  an  oxidative  sequence.  Plasma  contains  a  vari-
ety  of  antioxidants,  namely  vitamin  C  and  thiol  groups.
The  loss  of  plasma  antioxidants  may  indicate  the  ongo-
ing  biological  oxidative  stress.  When  oxidants  increase  and
antioxidant  fail,  a  situation  of  oxidative  stress  ensues  that
leads  to  excessive  molecular  damage  and  tissue  injury.16
Despite  some  limitations,  plasma  vitamin  C  has  served  as  the
index  for  the  biochemical  evaluation  of  vitamin  C  status.23
Plasmatic  vitamin  C  is  particularly  important  because  the
gas  phase  of  cigarette  smoke  induces  lipid  peroxidation  in
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Figure  2  Concentration  of  plasma  vitamin  C  and  sulphydryl  groups
mean ±  SEM.  COPD  patients  had  a  signiﬁcant  (p  <  0.001)  decrease  in  
with control  group.lasma  in  vitro  that  is  decreased  by  vitamin  C.27 In  addition,
s  a  consequence  of  the  role  of  oxidative  stress  in  the  patho-
enesis  of  emphysema,  it  has  been  suggested  that  dietary
ntioxidants  such  as  vitamins  A,  C  and  E  could  have  a  pro-
ective  effect  in  smokers.3 In  addition,  other  studies  showed
ecreased  total  antioxidant  capacity  in  patients  with  COPD
s  compared  to  control  subjects.28--30 However  discrepant
esults  were  found  in  other  studies  regarding  the  relation-
hip  between  antioxidant  status  and  pulmonary  functions  in
OPD  patients.14 Other  studies  failed  to  ﬁnd  a protective
ffect  of  antioxidants  on  the  lung  function.30 The  molecu-
ar  mechanisms  relating  to  antioxidant  defence  in  COPD  is
till  lacking.31,32 In  this  study  we  found  that  COPD  patients
ad  a  signiﬁcant  (p  <  0.001)  decrease  in  antioxidant  sta-
us  (vitamin  C  and  sulphydryl  groups)  when  compared  with
ontrol  group.  The  signiﬁcant  decrease  in  vitamin  C  and
ulphydryl  groups  associated  to  COPD  patients  agrees  with
he  hypothesis  that  glutathione,  the  most  abundant  cellu-
ar  non-protein  sulphydryls,  and  the  glutathione  redox  cycle
ay  be  regarded  as  an  antioxidant  mechanism  involved  in
he  protection  against  oxidative  stress.33 We  did  not  ﬁnd
 signiﬁcant  difference  in  the  antioxidant  status  between
on-smokers  and  smokers  healthy  subjects  and  between
on-smokers  and  ex-smokers  patients  but  we  did  observe
 tendency  toward  a  decrease  in  vitamin  C  associated  to
OPD  patients  with  smoking  habits.
The  difference  of  age  between  controls  and  COPD
atients  could  be  a  limitation  in  our  study.  In  order  to
bserve  the  effect  of  age,  we  compared  the  results  in
ealthy  subjects  younger  than  50  years  and  those  over
0  years.  We  found  no  signiﬁcant  difference  in  plasma
DA  levels  and  antioxidant  status  associated  to  age.  Our
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24  
bservation  is  supported  by  the  studies  of  other  authors  who
ound  no  relationship  between  plasma  antioxidant  capacity
nd  protein  sulphydryls  with  age  in  healthy  subjects.21,28
ther  studies  reported  no  age  dependent  change  in  the
lasma  MDA  levels  in  the  general  population.34,35 In  addi-
ion,  other  authors  have  found  a  marked  reduction  in  MDA
ssociated  to  chronic  airway  disorders,  particularly  COPD.  It
as  been  suggested  that  the  increase  in  MDA  levels  related
o  the  pathophysiology  of  COPD  may  be  a  promising  marker
f  oxidative  stress  in  chronic  pulmonary  diseases.17
In  our  study  oxygen  therapy  was  not  analyzed.  However
he  effect  of  this  therapy  in  oxidative  stress  in  COPD  patients
s  still  controversial.  Our  results  show  a  signiﬁcant  difference
n  oxidative  stress  and  antioxidant  status  between  controls
nd  COPD  patients  (with  or  without  oxygen  therapy).  No  sig-
iﬁcant  difference  was  found  to  be  associated  with  oxygen
herapy.  Further  studies  are  required  to  clarify  the  effects
f  oxygen  therapy  in  COPD  patients.
In  conclusion,  this  study  showed  that  elevated  levels  of
BARS,  namely  the  end  product  of  oxidant  stress  appears
o  be  more  pronounced  in  COPD  patients.  Concomitantly,  a
igniﬁcant  decrease  in  the  protective  antioxidant  responses
as  found  to  be  associated  to  COPD  in  both  non-smokers  and
x-smokers  patients.  The  imbalance  between  oxidants  and
ntioxidants  seems  to  be  an  important  event  associated  to
he  development  of  COPD.  This  could  provide  therapeutic
mplications  in  the  future.
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